Precision at Scale: How Generics Win with the Right Support

Generic pharma plays a different game than its specialist counterpart. It is not about new discoveries or blockbuster headlines. It is about reliability, scale and access: making sure everyday medicines actually reach the people who need them, at prices they can afford.

That is not simple work. It means juggling strict regulations, tight margins and global supply chains, often without the recognition the impact deserves. Our role is not to disrupt it but to support it, helping teams do more with less and stay ahead of the paperwork.

In the US, generic drugs account for about 90% of all prescriptions filled, yet they represent only about 20% of total drug spending. According to the Association for Accessible Medicines, generics saved the US healthcare system $408 billion in 2022 alone and over $2.9 trillion in the last decade.^[1]

The vital role of affordable generics was shown clearly in India with the cancer drug Nexavar. The original, patented by Bayer, cost Rs 2.8 lakh per month. The Indian Patent Office granted the first-ever compulsory licence to Natco Pharma, which produced a generic version at Rs 8,880 per month, on the grounds that the original was neither reasonably affordable nor sufficiently available.^[2]

How accessible medicines are made

Understanding how generic pharma works helps make sense of drug costs, and of why some medicines are more readily available than others. It is especially clear in places like India, often called the pharmacy of the world, where affordable generics are commonplace.^[3] Studies there have shown specialty drugs can cost patients significantly more, up to 41% more in one comparison, than the equivalent generic from the very same manufacturer.^[4]

• The goal: access and affordability Offering lower-priced alternatives, increasing access for patients, and helping manage healthcare budgets globally.

• Everyday treatments Typically widely used medicines in familiar forms, tablets and capsules, for common conditions like high cholesterol, blood pressure, infections and pain relief.

• Matching the original Generic companies must scientifically prove their version is bioequivalent to the original: that it works the same way in the body and is just as safe and effective. That takes careful testing, though not the multi-year clinical trials a new molecule needs.

• Efficiency through strategic outsourcing Partnering with specialized organizations for certain tasks lets generic companies stay flexible and focus on efficient, large-scale production. Making those collaborations run smoothly is where the operational difficulty sits.

Overcoming obstacles: the path for generic pharma

While essential, the path is not smooth. Generic companies navigate several common challenges, particularly in major hubs like India.

• The regulatory tightrope Intricate regulations that vary between regions and change frequently require significant resources, and the stringent quality standards demanded by international export markets add another layer.

• Quality is non-negotiable Consistent quality and the threat of substandard or counterfeit product are constant priorities, vital to patient safety and reputation. Managing that across both in-house and outsourced operations is the hard part.

• Supply chain and cost squeeze Dependence on imported active pharmaceutical ingredients, sometimes from limited sources, creates exposure to disruption. The market is crowded, which drives intense price competition on already thin margins, sometimes compounded by government price controls.

• The patent puzzle Navigating complex patent law and managing potential disputes over generic versions takes careful legal attention and can be costly.

• Juggling resources Managing internal resources while overseeing outsourcing partners is its own discipline. Outsourcing brings flexibility, and it demands oversight to keep timelines and quality standards met.

Smarter generics: how AI lends a hand

You might think that because generic companies are not discovering drugs from scratch there is less room for AI. It turns out to be a valuable tool for them too.

• Support for big production runs Because generic manufacturing focuses on large-scale production of established forms, AI improves oversight and coordination when manufacturing is outsourced, helping manage CDMO relationships so quality stays consistent across the supply chain.

• Faster formulation Analysis can help pinpoint the mix of ingredients and manufacturing steps needed to achieve bioequivalence more quickly, reducing development time whether the work is internal or with a partner.

• Cutting through regulatory red tape Approval means dealing with huge amounts of paperwork. Tools can compile these complex documents, check them for errors or omissions, and track changing requirements across countries.

• Sharper market strategy Analyzing patent expiry dates, market sizes and likely competition helps companies decide which generic opportunities are actually worth pursuing.

In short, AI offers generic pharma ways to do what it already does, faster and more reliably, which ultimately brings affordable medications to patients sooner after brand-name patents expire.

References

1. [1]Association for Accessible Medicines. 2023 U.S. Generic and Biosimilar Medicines Savings Report. accessiblemeds.org
2. [2]The Hindu. Indian company gets licence to manufacture and sell patented cancer drug.
3. [3]India, the pharmacy of the world, needs stronger government support. orfonline.org
4. [4]A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India.